Fencafen

Quick links to important sections

Fencafen

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fencafen

Quick Facts

Property Description
Active Ingredients Ergotamine Tartrate, Caffeine
Form Oral tablet, Rectal suppository
Pharmacological Class Antimigraine Agent, Ergot Alkaloid Combination
General Purpose Acute intervention of vascular headaches
Type Fixed-dose combination medication

Fencafen: Definition and Pharmacological Classification

Fencafen is defined as a fixed-dose combination medication intended for the acute management of severe vascular headaches, including migraine episodes. Pharmacologically, it is classified as an Antimigraine Agent and belongs to the Ergot Alkaloid Combination class, a grouping associated with targeted efficacy against the underlying vascular mechanisms of these attacks. This formulation is a potent prescription product designated for intervention in debilitating headache episodes.

Composition and Origin: The Role of Ergotamine and Caffeine

The medication's core features two active components: Ergotamine Tartrate, a semi-synthetic ergopeptine derived from the ergot fungus, and Caffeine, a synthetic xanthine derivative. This dual composition is a distinctive feature of the formula. The combination leverages the role of Caffeine, which enhances the absorption of Ergotamine and augments the overall vasoconstrictive effect required to abort an acute headache.

General Therapeutic Purpose and Available Forms

The overall therapeutic purpose of Fencafen is to interrupt the progression of severe vascular headaches by rapidly addressing the excessive dilation of cranial blood vessels. The drug is typically employed when a patient experiences a clear-cut vascular headache attack. Fencafen is supplied as an oral tablet and, notably, as a rectal suppository. The availability of the suppository form offers a crucial alternative administration route for patients who cannot tolerate oral medication due to associated severe nausea or vomiting during the acute phase of their episode.

Regulatory References

  1. Ergotamine/Caffeine - StatPearls - NCBI Bookshelf

What side effects are possible with Fencafen?

Possible side effects and safety information

This section describes the officially documented adverse reactions and safety characteristics of the Ergotamine Tartrate and Caffeine combination, as defined by government regulatory authorities.

Adverse Reaction Classifications

The most commonly classified side effects reported in official documents are related to the gastrointestinal and nervous systems. These frequently include nausea, vomiting, dizziness, and paresthesia (numbness or tingling). Less common effects often involve pain in the extremities or diarrhea.

Adverse reactions are formally grouped by the body system affected:

  • Vascular/Cardiac Disorders: Effects related to vasoconstriction, including peripheral ischemia, changes in heart rate (tachycardia or bradycardia), and hypertension.
  • Gastrointestinal Disorders: Common events like nausea, vomiting, and abdominal pain.
  • Nervous System Disorders: Effects such as dizziness, weakness, and paresthesia.

Serious Safety Considerations

The official labeling documents severe, rare, but clinically important adverse reactions primarily stemming from intense vasoconstriction. The most serious concern is Ergotism, a severe systemic toxicity that can lead to signs of peripheral vascular ischemia, myocardial ischemia, or gangrene. Serious complications such as myocardial infarction (heart attack) and cerebral ischemia are also documented.

Safety Limitations and Restrictions

Certain high-risk situations define regulatory restrictions on the use of this medication. The combination is strictly contraindicated in patients with pre-existing cardiovascular diseases, uncontrolled hypertension, or severe hepatic (liver) or renal (kidney) impairment. It is also contraindicated during pregnancy and for use with strong CYP3A4 inhibitors, as this combination significantly increases the risk of severe ergot toxicity. Furthermore, frequent or indiscriminate use is officially associated with the risk of developing Medication Overuse Headache (rebound headache).

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Fencafen is associated with taking more than the prescribed amount. It is important to know the signs of overdose and the required emergency actions, as symptoms can be severe and life-threatening.

Documented Overdose Symptoms

Symptoms reported in cases of overdose or severe toxicity involve the central nervous system, cardiovascular system, and gastrointestinal tract. These manifestations may include:

  • Circulatory/Vascular: Pain, numbness, or tingling sensation; cold, pale, or bluish discoloration of the hands and feet (cyanosis); lack of a detectable pulse; and fainting or lightheadedness.
  • Neurological: Drowsiness, dizziness, severe sleepiness, seizures, loss of consciousness, or coma.
  • Gastrointestinal: Nausea and severe vomiting.

Emergency Actions

If an overdose is suspected, immediate action is required. Contact the Poison Control Helpline right away for advice. In cases where the individual exhibits the most serious symptoms, an immediate call to emergency services (e.g., 911) is essential:

  • Immediately call emergency services if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened (unconsciousness or coma).

Overdose risk is elevated when the maximum prescribed dose is exceeded, or when other medicines containing similar components are consumed simultaneously, potentially leading to systemic toxicity. Always use this medication strictly as directed by a healthcare professional.

Therapeutic Uses of Fencafen

What Fencafen Treats: Main Uses and Benefits


The core therapeutic role of Fencafen is applied in clinical settings that involve acute or unstable symptom patterns, which may be relevant for easing symptoms related to severe vascular headaches. This approach is generally applied across conditions involving episodic or fluctuating manifestations that create noticeable physiological strain. The medication's role is commonly used to help with managing symptom clusters that may become intense or disruptive, offering supportive relief when symptoms create noticeable physiological strain.

Fencafen is considered relevant for easing symptoms associated with migraine headaches and certain severe variants like histaminic cephalalgia (cluster headaches).

Fencafen is often used during phases when patients experience severe, debilitating pain, and where short-term symptomatic assistance is needed. It provides support that helps ease the overall symptom burden, and offers symptomatic relief that helps patients cope more steadily with difficult episodes. The therapeutic benefit is generally applied in addressing symptom clusters that may become intense or disruptive, including associated manifestations such as severe nausea and vomiting.

Quick Fact: Relief for Acute Vascular Pain
Fencafen is commonly used across conditions presenting with acute episodes and is relevant for managing symptoms that interfere with daily comfort and stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Scope

Fencafen (Ergotamine/Caffeine) is officially labeled for use in a highly restricted population, primarily due to the potent vasoconstrictive properties of the ergotamine component. The medicine is sanctioned for adults (18 years and older) for the acute treatment of vascular headaches.

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label): Adults (18 years and older).
Populations for whom use is not recommended: Pediatric population (under 18 years): Safety and efficacy have not been established.
Populations for whom use is contraindicated: Pregnant women or women who may become pregnant (Absolute prohibition).
Lactation Status: Contraindicated or Not Recommended in breastfeeding women.

Condition-Specific Eligibility Rules

The following conditions represent absolute contraindications and prohibit the use of Fencafen, as stated in official labeling:

  • Cardiovascular Conditions: Peripheral Vascular Disease, Coronary Heart Disease, or Uncontrolled Hypertension.
  • Organ Function Impairment: Severe Hepatic Impairment (liver disease) and Severe Renal Impairment (kidney disease).
  • Systemic Conditions: Sepsis (severe systemic infection).
  • Drug-Drug Interactions: Concomitant use with potent CYP3A4 inhibitors (e.g., certain macrolide antibiotics and HIV protease inhibitors) is strictly forbidden due to the risk of life-threatening ergot toxicity.

Connection to the Overall Eligibility Profile

Regulatory documents define the eligible population as otherwise healthy adults who are free of major cardiovascular, hepatic, or renal comorbidities. The eligibility criteria are primarily composed of a comprehensive list of absolute contraindications that formally exclude individuals with specific vascular diseases, organ dysfunction, and those using certain co-administered medications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes documented drug-drug, drug-food, and drug-product interactions for Fencafen as detailed in official regulatory information.


Contraindicated Combinations

The most serious interaction involves co-administration with potent CYP 3A4 inhibitors. These medicines can significantly increase the concentration of Fencafen in the body, leading to a serious and potentially life-threatening condition called ergotism, which is characterized by severe vasospasm and ischemia. Medicines in this category include specific macrolide antibiotics (e.g., erythromycin, clarithromycin), HIV protease inhibitors (e.g., ritonavir, indinavir), and azole antifungals (e.g., ketoconazole, itraconazole). Fencafen is also contraindicated with other ergotamine-containing drugs.

Other Clinically Significant Interactions

Interactions based on pharmacodynamic effects are documented with other vasoconstrictive agents. Co-administration with other vasoconstrictors, including sympathomimetics and certain anti-migraine medications known as triptans (5-HT1B/1D agonists), may lead to additive effects, increasing the risk of peripheral or cerebral ischemia. Regulatory guidance specifies that triptans must not be used within 24 hours of Fencafen. The beta-blocker propranolol is also noted to potentiate Fencafen's vasoconstrictive action.

Drug-Food/Lifestyle Interactions

Consumption of grapefruit or grapefruit juice may elevate Fencafen blood levels. Additionally, nicotine is known to cause vasoconstriction and may contribute to a greater ischemic response when used concurrently with Fencafen.

Mechanism of Action

How Fencafen Works

Fencafen's pharmacodynamic action results from the combined influence of Ergotamine and Caffeine on the cranial vasculature and neuro-vascular signaling pathways.

Ergotamine functions as a partial agonist at the 5-HT1B receptors on cranial vessel smooth muscle, which directly initiates vasoconstriction. This action contributes to the modulation of vascular tone by reducing the dilation of the vascular tissue. Concurrently, 5-HT1D agonism on presynaptic trigeminal nerve endings modulates the release of pro-inflammatory neuropeptides, thereby regulating the signal propagation of neurogenic inflammation.

Caffeine acts as a non-selective antagonist at adenosine receptors ( A2A). By blocking these purinergic receptors, Caffeine prevents adenosine-mediated vasodilation, enhancing the vasoconstrictive effect on the cerebral circulation. This mechanism provides synergy, contributing to a reduction in cerebral blood flow's vasodilatory influence.

Frequent activation of these vasoconstrictive receptors can lead to functional desensitization, establishing receptor over-reliance. Withdrawal may result in rebound vasodilation, a physiological constraint of the mechanism.

Dosage and Administration Information

Fencafen is prescribed solely for the acute intervention of severe vascular headaches and is characterized as an intermittent rescue therapy, not a preventative or chronic daily treatment. Administration must begin at the first sign of the attack to ensure alignment with standard use patterns. The medicine is available as an oral tablet and a rectal suppository, providing alternative routes for administration. The rectal suppository contains a higher concentration of ergotamine (2 mg vs. 1 mg) and is strictly for rectal insertion, with specific instructions to chill the suppository if it has softened prior to use.

Official Dosing and Frequency

Formulation Initial Dose Subsequent Dosing Limit Maximum Dose per Attack Maximum Dose per 7-Day Period
Oral Tablet 2 tablets 1 tablet every 30 minutes, as needed 6 tablets 10 tablets
Rectal Suppository 1 suppository 1 suppository after 1 hour, as needed 2 suppositories 5 suppositories

The mandatory waiting periods between doses (30 minutes for the oral tablet and 1 hour for the suppository) are critical components of the regimen. These strict temporal and cumulative dosage limits control the total systemic exposure to the active ingredients. The safety and effectiveness of Fencafen have not been established for use in the pediatric population.

Recent Clinical Evidence

Research evidence / Overview of studies for Fencafen

Evidence for use in Acute Migraine Disorders

Research exploring Fencafen for studies related to acute symptoms of migraine headaches has relied primarily on short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time and often included adult patients experiencing headaches that were classified as moderate to severe. Studies monitored outcomes related to physical discomfort, specifically measuring the reduction of headache intensity and the duration of pain response. Comparative research also explored this combination against other agents.

Findings describe patterns observed in the studies related to measured headache response at fixed intervals (typically 1 to 4 hours after treatment). Historically, some evidence indicated that the measured outcomes of the oral formulation were not always significantly different from a placebo. More modern comparative research examined Fencafen against comparator drugs (e.g., triptans). These studies report how symptoms evolved in the observed populations, indicating that the reported rates of achieving a pain-free state or the speed of response were generally observed differently than patterns associated with the comparator drugs. Data show patterns where specific side-effects were observed in some studies at a higher frequency compared to the comparator drugs.

Evidence for use in Cluster Headaches (Histaminic Cephalalgia)

Research examined Fencafen for its use in cluster headaches, which are conditions associated with acute or disruptive episodes. The research foundation for using ergot-based agents in this context largely stems from historical clinical observations and case series rather than contemporary RCTs focused specifically on the Fencafen combination. Evidence concerning the speed of symptom change for the oral and rectal formulations suggests the onset of measured outcomes may be delayed relative to the typical timeframe of the attack. Comparative evidence is lacking for the specific Fencafen combination against the current standard of care for cluster headaches.

What is Still Uncertain About Fencafen Research

The research exploring Fencafen has identified several key areas where certainty remains low or where comparative evidence is lacking. The results apply only to the populations studied and may not extend to all users. A significant documented limitation involves inconsistent absorption of the medicine, particularly the oral form, which can lead to variable measured outcomes across studies. The follow-up durations were limited across the main clinical trials, meaning that long-term effects are not fully established. Furthermore, data for certain groups remain insufficient, specifically for both pediatric and geriatric populations.

Key Studies & References

  1. Acute Treatment of Cluster Headaches (Clinical Review discussing ergot use and limitations in cluster headache)
  2. Cafergot (ergotamine tartrate and caffeine) Tablet, Film Coated Official FDA Drug Label

Frequently Asked Questions (FAQ)

Common questions about Fencafen (FAQ)


Q: Is Fencafen a type of pain reliever?

A: Fencafen is classified in official documents as an antimigraine agent, and its purpose is to interrupt the progression of a vascular headache attack. The medication achieves this through its effects on cranial blood vessels, which is described as different from a general pain reliever (analgesic). Regulatory information indicates that the drug is used for acute intervention, not for typical pain relief.


Q: How quickly does Fencafen start to work?

A: Regulatory documents state that administration is indicated to begin at the first sign of an attack. Official research studies have often monitored the measured outcomes related to symptom reduction at fixed time intervals after treatment, typically ranging between one to four hours.


Q: Does Fencafen have long-term effects that people should know about?

A: Official information indicates that the safety and effects of continuous, long-term use are not fully established. However, frequent or indiscriminate use is formally associated with the risk of developing Medication Overuse Headache (rebound headache). Rare, serious fibrotic complications have also been reported in official warnings.


Q: What happens if I stop taking Fencafen suddenly?

A: Regulatory documents note that withdrawal symptoms, such as rebound headaches, have been reported in rare instances. Regulatory information notes this pattern is typically reported among patients who have used the medication frequently or indiscriminately over extended periods of time.


Q: Why do people say Fencafen helps with [specific, broad condition covered by drug]?

A: The drug works due to the combined action of its two active ingredients. Ergotamine works by initiating the narrowing of cranial blood vessels, while Caffeine helps enhance the absorption of Ergotamine and strengthens this vessel-narrowing effect. This specific mechanism is described as interrupting the underlying vascular progression of the headache.


Q: Does Fencafen interact with common vitamins or supplements?

A: Regulatory documents list specific drug-drug and drug-food interactions, but they do not list specific vitamins or supplements as contraindications. However, official information indicates that a healthcare provider should be informed of all medicines, supplements, and herbal remedies being used, as potential interactions may occur.


Q: Is it safe to drink coffee while taking Fencafen?

A: Fencafen itself contains caffeine as one of its active ingredients. Regulatory information indicates that high total caffeine intake, including from additional sources like coffee, may potentially lead to increased common side effects such as nervousness, shakiness, or a fast heartbeat.


Q: Can older adults use Fencafen?

A: Fencafen is officially sanctioned for use in adults (18 years and older). Official clinical research data is sometimes noted as being insufficient specifically for geriatric populations. The official label notes that geriatric patients may be more sensitive to certain effects, such as reduced peripheral circulation, compared to younger adults.


Q: Is Fencafen available over the counter, or is it prescription only?

A: Fencafen is classified in regulatory documents as a potent prescription product. It is only dispensed through a licensed pharmacy with a valid prescription from a qualified healthcare professional and is not available over-the-counter.


Q: What is the intended duration of action for Fencafen after a dose?

A: Official documents do not specify a fixed duration of action for the medicine's effect. However, they indicate that in clinical studies, researchers monitored the measured change in patient symptoms over fixed intervals, typically ranging from one to four hours after a dose.


Q: Is Fencafen addictive or habit-forming?

A: Regulatory documents do not use the term 'addictive' but caution against frequent or indiscriminate use. This is due to the potential risk of developing Medication Overuse Headache (rebound headache), which is a condition linked to dependency on pain or headache medication.


Q: Is Fencafen known to interact with blood pressure medications?

A: Yes, regulatory documents indicate that Fencafen is contraindicated in patients with uncontrolled high blood pressure. It is also known to interact with certain blood pressure medications, such as the beta-blocker propranolol, potentially increasing its vessel-narrowing action.


Q: Is it possible to develop a tolerance to Fencafen over time?

A: The mechanism of action described in official documents suggests that frequent activation of the relevant blood vessel receptors can lead to functional desensitization. This is a form of tolerance that can result in rebound vasodilation if the drug is stopped.


Q: Does Fencafen have a warning about driving or operating machinery?

A: Official information indicates that side effects such as dizziness and weakness are possible. Activities requiring mental alertness, such as driving or operating complex machinery, should be avoided until an individual knows how the drug affects them.


Q: Can Fencafen cause skin reactions or rashes?

A: Official documentation notes that allergic reactions are possible with this medication. Signs of an allergic reaction, such as a rash, hives, or itching, should be reported immediately to a healthcare provider.


Q: What if I'm taking Fencafen and I feel no different?

A: Studies and regulatory documents have noted that the effectiveness of the drug may vary across different patients. Factors such as inconsistent absorption have been noted, and in some studies, the measured effect was not always significantly different from a placebo. Official product information suggests that individuals should consult with their healthcare team if they do not get relief from the medication.


Q: Are there any known interactions between Fencafen and alcohol?

A: While not listed as a formal contraindication, some patient information indicates that consumption of alcohol should be avoided or limited while taking Fencafen. Alcohol may increase certain central nervous system side effects of the medication, such as dizziness.


Q: How long does Fencafen stay in your system?

A: Regulatory information indicates that the elimination half-life of the Ergotamine component is approximately two hours. This is the time it takes for half of the dose to be removed from the body. However, the total time the drug's effects last can vary based on individual absorption.


Q: Can Fencafen be taken with common pain relievers like acetaminophen?

A: Official regulatory warnings list specific contraindicated drug classes. They indicate that a healthcare professional should be consulted before taking other pain relievers, as this is necessary to ensure no interaction could increase side effects or toxicity.


Q: What are the signs of an allergic reaction to Fencafen?

A: Signs of a serious allergic reaction, according to official patient information, may include a rash, hives, or itching. More severe signs include swelling of the face, lips, tongue, or throat, or difficulty breathing, which are symptoms officially noted as requiring immediate medical evaluation.


Q: Is it normal to feel a change in appetite while taking Fencafen?

A: Official safety information lists several common gastrointestinal side effects, including nausea, vomiting, and diarrhea. While changes in appetite are not listed as one of the most common events, they are noted as possible adverse events associated with the drug.


Q: Is Fencafen a controlled substance?

A: The Fencafen combination product is categorized as a prescription-only (Rx-only) medication. Although the ergotamine component is listed as a regulated chemical in some jurisdictions, the finished product itself is not typically classified as a controlled substance in the way narcotics are.


Q: Is Fencafen known to interact with herbal remedies?

A: Official documents list specific drug interactions but generally indicate that a healthcare provider should be informed of all medicines, supplements, and herbal remedies being used. This is a common precaution to check for potential and unknown interactions.


Q: What happens if a dose of Fencafen is missed?

A: Because this medication is only for the acute intervention of a headache, regulatory information states that double or extra doses should not be taken if one is missed. The drug is designated to be taken solely at the first sign of a headache attack.


Q: Does Fencafen affect sleep patterns?

A: Fencafen contains caffeine, which is a stimulant. While official labels list common nervous system effects like dizziness and restlessness, the regulatory guidance indicates that caution should be exercised. The labels do not specifically state that the drug causes insomnia or disruptions to sleep patterns.

How should Fencafen be stored and disposed of?

Fencafen storage requirements vary by formulation and must be strictly followed to ensure product stability and safety.

Scope Element Oral Tablet Rectal Suppository
Temperature Requirements Controlled room temperature: 20 C to 25 C (68 F to 77 F). Store in a refrigerator.
Environmental Protection Protect from light and moisture; keep from excessive heat and freezing. Protect from moisture and freezing.
Packaging Rules Keep in the container it came in, tightly closed, and light-resistant. Keep in the sealed foil until just prior to use.

All forms must be kept out of the sight and reach of children. For disposal of unused or expired Fencafen, the best option is a community drug take-back program. If no take-back program is available, the medicine should be mixed with an undesirable substance, placed in a sealed container, and thrown into the household trash; do not flush down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fencafen found in:

A-Z Index: